Peptides for Loose Skin After Weight Loss: Evidence Protocol

You lost the weight. The 40 pounds from a long cut, the 60 pounds from Ozempic, the 100 pounds from bariatric surgery. Congratulations, and welcome to the other problem nobody warned you about: a belly that hangs, arms that wing, inner thighs that chafe. The fat is gone, but the skin is still there.

If you spend any time in post-weight-loss communities (the subreddits, the Facebook groups, the comment sections of every GLP-1 YouTube video), you will see the same question asked every week. Will peptides fix this? Can GHK-Cu tighten my stomach? Should I run BPC-157 and TB-500? Do I need surgery, or will CJC-1295 and ipamorelin give me my old skin back?

This article answers those questions honestly. Peptides are not magic. But they are not nothing either, and nobody else has written a serious protocol that stacks the five layers that actually matter: topical GHK-Cu, injectable peptides, GH secretagogues, energy-based devices, and the boring stuff (protein, training, collagen supplements) that runs underneath all of it. I will also show you the bloodwork to run while you do it, because flying blind on a GH peptide protocol is how you trade loose skin for a new set of problems.

Why loose skin happens (and why peptides aren't magic)

Skin laxity after significant weight loss is not a single problem. It is two structural failures stacked on top of each other, and neither recovers on its own.

The first failure is in the collagen matrix. Thick, organised, cross-linked type I collagen fibres get replaced by thin, misaligned, loosely arranged ones after prolonged mechanical stretch, even when total collagen content stays broadly similar (Rocha et al., 2021). The architecture is what gives skin its recoil, not the raw count, and the architecture degrades. One histomorphometric analysis of post-bariatric abdominal skin found significant collagen depletion in both the epigastrium (p = 0.001) and hypogastrium (p = 0.007) after massive surgical weight loss (Orpheu et al., 2010).

The second failure is architectural, and it is the one that truly sinks you. Elastin fibres in the papillary dermis are almost entirely destroyed after sustained obesity. The elaunin and oxytalan fibre subtypes (the scaffolding that mature elastic fibres grow on) are lost completely, leaving only short fragmented remnants in the reticular dermis (Sami et al., 2015). The cruel irony: raw elastin fibre count can actually go up, but the architecture is destroyed, so the skin sags anyway. More elastic fibres, zero elastic recoil. That is why your skin feels thick but still hangs.

Speed of weight loss matters mechanically. A Hany 2024 comparison of post-bariatric vs non-bariatric patients found elastin content was higher in people who lost weight non-surgically (6.8%) than those who lost it via bariatric surgery (5.0%), p = 0.029 (Hany et al., 2024). The faster and more metabolically violent the loss, the less time the dermis has to reorganise before the fat substrate disappears. GLP-1 agonists (semaglutide, tirzepatide, retatrutide) sit closer to the bariatric end of this spectrum than the "slow cut" end, which is why the Ozempic-body phenomenon looks clinically identical to post-bariatric laxity at a lower absolute weight loss.

Age is the ceiling you cannot negotiate with. Fibroblasts from donors aged 80+ produce type I procollagen at 56 +/- 8 ng/ml compared to 82 +/- 16 ng/ml in donors aged 18 to 29, roughly a 32% reduction in synthetic capacity (Varani et al., 2006). Skin collagen decreases by about 1% per year after 30. A 25-year-old losing 40 pounds has substantially more remodeling potential than a 50-year-old losing the same amount, and no peptide will change that equation.

What peptides can and cannot do

Peptides do three things for loose skin. They stimulate fibroblasts to produce new collagen (GHK-Cu, IGF-1 from GH secretagogues). They promote angiogenesis and tissue remodeling (BPC-157, TB-500). They modulate inflammation so collagen deposition proceeds in an organised way rather than as fibrotic scarring.

Peptides do not rebuild destroyed elastic fibre architecture. Once the elaunin and oxytalan scaffolding is gone, no molecule currently available to outpatient medicine puts it back. That is the honest ceiling on what peptides can deliver, and it is why surgery remains the only solution for severe laxity.

The 6-month severity-stratified protocol

The single biggest mistake post-weight-loss patients make is running the same protocol regardless of how much skin damage they actually have. Someone who lost 15 pounds in a contest prep cut does not need the same stack as someone who dropped 70 pounds on tirzepatide. Match the intervention to the damage.

The Pittsburgh Rating Scale is the validated clinical tool for grading this. It scores 10 body regions from 0 (normal) to 3 (severe), with good interobserver reliability (kappa = 0.68) (Song et al., 2005). You do not need to formally score yourself, but the mild/moderate/severe framework maps cleanly to real protocols.

Mild laxity (under 10 kg / 20 lb lost, age under 35). Skin laxity is limited to fine wrinkling, the pinch test rebounds with visible elasticity, and Pittsburgh scores are 0 to 1. Protocol: topical GHK-Cu 2% serum nightly, home microneedling roller (0.5 mm) weekly, hydrolyzed collagen 10 g/day with 1 g vitamin C, heavy compound training, adequate protein at 1.6 to 2.2 g/kg/day. Injectable peptides are overkill at this level. Expected outcome over 6 months: visible improvement in skin texture and fine wrinkling, minimal to no persistent laxity.

Moderate laxity (10 to 25 kg / 20 to 50 lb lost, mixed ages). Pittsburgh 1 to 2, mild to moderate pinch test lag, visible but not severe skin redundancy on the abdomen or inner arms. This is where the full peptide stack actually earns its keep. Protocol: topical GHK-Cu + alternating tretinoin, CJC-1295 no-DAC 100 mcg + ipamorelin 200 to 300 mcg pre-bed, BPC-157 250 to 500 mcg twice daily during the first 8 weeks, RF microneedling every 4 to 6 weeks for 3 to 4 sessions, daily red light therapy, collagen supplementation, training, bloodwork monitoring. Expected outcome: 10 to 30% subjective improvement, with photographic progress visible by month 3.

Severe laxity (25+ kg / 50+ lb lost, or age 45+, Pittsburgh 2 to 3). True panniculus formation, no skin rebound on pinch, the dermis has lost its elastic architecture. This is a surgical problem. Running peptides here is not wasted (they still support what improvement is possible), but expecting them to substitute for a panniculectomy or brachioplasty is setting yourself up to fail. The honest path is 12 to 18 months of full protocol + training + body composition recovery, then a surgical consultation with realistic expectations.

Topical GHK-Cu: the most evidence-backed layer

If you only run one thing on this list, run topical GHK-Cu. It has the cleanest mechanism, the longest history, and the lowest risk of any peptide on the skin.

GHK-Cu (glycyl-histidyl-lysine copper) is a naturally occurring human tripeptide first described by Loren Pickart in the 1970s. The "GHK triplet" sequence actually exists inside the alpha-2(I) chain of type I collagen, and is released when collagen is damaged, making GHK-Cu a native repair signal (Maquart et al., 1988). When you apply it topically, you are not injecting a foreign molecule; you are amplifying a signal your own dermis uses to initiate remodeling.

The mechanism has three pieces. First, direct fibroblast activation: GHK-Cu stimulates collagen synthesis at picomolar to nanomolar concentrations, with pro-alpha-1(I) collagen mRNA upregulated at the pretranslational level, and effects are TGF-beta independent (Maquart et al., 1993). Second, MMP modulation: GHK-Cu upregulates matrix metalloproteinases to clear damaged, glycated collagen, while simultaneously stimulating new collagen and anti-proteases (TIMPs). This dual synthesis/clearance action distinguishes it from simple collagen boosters. Third, anti-glycation: GHK-Cu suppresses protein glycation and inhibits TNF-alpha and thromboxane release (Pickart, 2008).

The anti-glycation angle matters specifically for bodybuilders. If you run GH, insulin, or MK-677, your connective tissue sees elevated advanced glycation end-product (AGE) accumulation. AGEs cross-link collagen and elastin into a stiff, brittle, non-compliant matrix that looks and feels exactly like aged skin. GHK-Cu is one of the few topical ingredients with documented anti-glycation activity.

The topical penetration problem

Here is the honest caveat: most of the mechanistic evidence comes from injected GHK-Cu or wound-chamber delivery. Topical GHK-Cu has a penetration problem because the molecule is hydrophilic and does not easily cross the stratum corneum. A Hur 2020 study found that conjugating GHK to oligoarginine (a cell-penetrating peptide) significantly improved both transdermal delivery and anti-wrinkle activity in ex-vivo skin models (Hur et al., 2020).

The practical workaround is microneedling. A Quinlan 2022 study combining home-based 0.2 mm microneedling twice weekly with topical growth factor serum over 3 months produced 17.6% improvement in skin texture, 17.3% improvement in wrinkle scores, and 12.4% reduction in red area across 11 subjects (p < 0.001) (Quinlan et al., 2022). The microchannels bypass the stratum corneum, which is the single largest delivery barrier for hydrophilic peptides.

A Byun 2016 case study in a 59-year-old male using a jet-spray device to drive a GHK-Cu formulation into crow's feet showed biopsy-confirmed increases in collagen, fibrillin-1, procollagen type I, and tropoelastin (Byun et al., 2016). Single case, but real biopsy data, not marketing claims.

Practical application

Standard cosmeceutical formulations are 2% GHK-Cu. The "2%" comes from industry convention, not a dose-finding trial, but it is the concentration where the commercial evidence base sits. Skin Actives, Paula's Choice, SkinMedica, and pharmacy compounded versions all deliver roughly this concentration. Research-grade GHK-Cu powder reconstituted at home carries endotoxin and purity risks that are not worth the savings.

Alternate nights with a low-strength tretinoin (0.025 to 0.05%) if your barrier can tolerate it. Tretinoin drives keratinocyte turnover and upregulates collagen synthesis via the retinoid receptor pathway, which is mechanistically complementary to GHK-Cu's fibroblast activation. Do not apply both on the same night during the first 4 to 6 weeks; you will over-sensitise your barrier.

Expect a purge. The "copper uglies" phenomenon (transient redness, flaking, small breakouts over 2 to 6 weeks) is anecdotally well documented in peptide communities and mechanistically plausible: GHK-Cu stimulates MMP activity to remodel existing collagen, which can visibly disrupt surface skin during the transition. It is not a formally documented adverse event in the peer-reviewed literature, but if it happens to you, push through for 4 to 6 weeks before deciding it is not working.

Injectable peptides: BPC-157 and TB-500 for tissue remodeling

BPC-157 and TB-500 are the two peptides most commonly stacked for recovery in the bodybuilding community, and their mechanisms do touch skin biology. Whether they meaningfully help post-weight-loss laxity is a harder question. The honest answer is: they help wound-healing models, but no study has ever tested them on cosmetic loose skin.

BPC-157 is a pentadecapeptide with preclinical evidence for angiogenesis, collagen deposition, and epithelial closure. In an alkali-burn rat model, topical BPC-157 accelerated wound closure, improved granulation tissue, and enhanced collagen deposition via VEGF-a upregulation and ERK1/2 phosphorylation (Huang et al., 2015). In a mouse burn model, BPC-157 cream reduced edema, increased capillary formation, advanced reticulin and collagen fibre formation, and improved tensile strength of burned skin, outperforming silver sulfadiazine (the clinical standard) (Mikus et al., 2001). In diabetic rats with full-thickness excisional wounds, BPC-157 (as PL14736) produced dose-dependent healing acceleration at 10 to 1,000 mcg/wound with greater mature collagen formation than becaplermin (Seveljević-Jaran et al., 2006).

TB-500 (the injectable fragment of thymosin beta-4) has the strongest human evidence of any peptide in the skin healing space, but again for wounds, not cosmetic skin. Kleinman and Sosne's review documented Phase 2 trials showing accelerated repair in patients with pressure ulcers, stasis ulcers, and epidermolysis bullosa wounds (Kleinman & Sosne, 2016). TB-500 is specifically anti-fibrotic and anti-scarring, making it the more mechanistically relevant of the two for skin quality rather than raw wound closure.

Be honest about the evidence gap

Loose skin from weight loss is not a wound. The dermis is intact but architecturally compromised. The mechanisms that help acute wounds heal faster (angiogenesis, fibroblast recruitment, cell migration) do something in loose skin, but whether it is clinically meaningful has never been tested in a single trial. Most of the BPC-157 positive literature comes from the Sikiric lab in Zagreb, and independent replication is limited. The first human pilot study of intravenous BPC-157 at 10 to 20 mg reported no adverse effects on cardiac, hepatic, renal, thyroid, or glucose biomarkers, but n = 2 (Lee & Burgess, 2025). That is not a safety signal, but it is not evidence either.

There is a real risk to flag. A 2003 study at the Journal of the National Cancer Institute found that viral overexpression of thymosin beta-4 in mice dramatically increased melanoma tumor size (mean 21.7 mm vs 13.3 mm) and lung metastatic nodule counts (46.7 vs 10.9), correlated with a 4.4-fold increase in tumor blood vessels (Cha et al., 2003). This was overexpression, not supplementation, and it does not prove TB-500 causes cancer in healthy people. It does mean that anyone with a history of malignancy should not run these peptides.

Practical dosing (community convention, not validated)

If you decide the risk/benefit ratio works for your situation:

• BPC-157: 250 to 500 mcg subcutaneous or intramuscular, twice daily, for the first 6 to 8 weeks of the protocol. Most benefit is front-loaded during active remodeling.
• TB-500: 2 to 5 mg twice weekly loading phase for 4 weeks, then 2 mg/week maintenance. Some protocols cycle it for 8 to 12 weeks then off.
• Stack rationale: BPC-157 drives new vessel formation and collagen deposition, TB-500 provides cell-migration scaffolding and anti-scarring. Mechanistically coherent; clinically unvalidated as a combination.

For the deeper mechanism and cancer-risk discussion, see the dedicated BPC-157 and TB-500 evidence review. I will not duplicate it here.

GH secretagogues: CJC-1295 and ipamorelin for collagen synthesis

This is where the protocol gets interesting and where the mechanism is cleanest. Growth hormone drives IGF-1. IGF-1 activates the LARP6 pathway in fibroblasts, which stabilises COL1a1 and COL1a2 mRNA and accelerates type I collagen synthesis (Blackstock et al., 2014). A Doessing 2010 study gave 33 to 50 mcg/kg/day of recombinant hGH for 14 days and measured a 3.9-fold increase in tendon collagen I mRNA and a 5.8-fold increase in muscle collagen protein synthesis, with zero effect on myofibrillar (contractile) protein (Doessing et al., 2010). GH's effect on connective tissue is specific and dose-responsive; it is not a mass-gain shortcut.

You can raise IGF-1 by injecting hGH, running MK-677, or stimulating your own pituitary with a GHRH analog plus a GHRP. The third option is the one that belongs in a loose skin protocol.

Why pulsatile beats sustained

The distinction between pulsatile GH release (CJC-1295 no-DAC + ipamorelin, injected before bed) and sustained GH elevation (MK-677, oral, continuous) is not bodybuilding bro-science. It is the reason one of these approaches preserves insulin sensitivity and the other does not.

Pulsatile delivery mimics physiological nocturnal GH secretion, which is what the pituitary does on its own when it is not being overridden. Sustained elevation (as from oral MK-677) bypasses this rhythm and drives predictable insulin resistance. The Nass 2008 two-year trial in healthy older adults on MK-677 25 mg/day documented a mean fasting glucose rise of 0.3 mmol/L (5 mg/dL), reduced insulin sensitivity, and 3 of 65 subjects discontinuing for glucose issues (Nass et al., 2008). Chapman's earlier MK-677 data was sharper: fasting glucose rose from 5.4 to 6.8 mmol/L (a 26% increase) in 4 weeks (Chapman et al., 1996).

Post-weight-loss patients frequently have borderline insulin sensitivity to start. Running MK-677 on top of that is exactly wrong. Run the pulsatile stack, preserve your insulin sensitivity, and cross-reference our MK-677 blood sugar monitoring guide and the GH insulin resistance deep-dive if you want the full HOMA-IR data.

CJC-1295 no-DAC + ipamorelin: the combo

CJC-1295 no-DAC is the short-acting form of CJC-1295 (half-life ~30 minutes), which matters because you want a pulse, not a plateau. Teichman's landmark RCT tested the with-DAC form at 30 to 60 mcg/kg and measured mean plasma IGF-1 elevation of 1.5 to 3-fold for 9 to 11 days (Teichman et al., 2006). The no-DAC form at 100 mcg 1 to 3 times daily produces smaller but more physiological pulses, which is what you want for dermal collagen synthesis without driving IGF-1 into supraphysiological territory.

Ipamorelin is the cleanest GHRP available. Raun 1998 confirmed that ipamorelin does not significantly raise ACTH or cortisol at doses more than 200 times the ED50 for GH release, distinguishing it from GHRP-6 and GHRP-2 (Raun et al., 1998). This cortisol neutrality matters for skin: chronic cortisol elevation degrades collagen, and GHRP-6 at therapeutic doses measurably raises it. Ipamorelin avoids the trade-off.

Practical protocol: CJC-1295 no-DAC 100 mcg + ipamorelin 200 to 300 mcg, subcutaneous, injected 30 minutes before bed. The pre-bed timing exploits the natural GH pulse 1 to 2 hours after sleep onset (the largest pulse of the day) rather than replacing it. Some practitioners add a morning dose for additional pulse; it is not essential for skin outcomes.

Alternatives: sermorelin and tesamorelin

Sermorelin is the shorter-acting GHRH analog that predates CJC-1295. Same receptor, same mechanism, shorter window, lower cost per dose. Fine substitute if CJC sourcing is problematic. The one caveat from the original Geref labeling: GHRH analogs can unmask subclinical hypothyroidism because they accelerate peripheral T4 to T3 conversion, sometimes dropping free T4 further. A Porretti 2002 cohort of 66 GH-deficient adults documented significant free T4 reduction on rhGH, with TSH unchanged (Porretti et al., 2002). Check baseline TSH and free T4 before starting any GH secretagogue, not just sermorelin.

Tesamorelin is the only FDA-approved GHRH analog, developed for HIV lipodystrophy. The Falutz pooled analysis of two Phase 3 trials at 2 mg/day SC documented visceral adipose tissue reduction of approximately 18% and significant IGF-1 elevation versus placebo (Falutz et al., 2010). The dual action (visceral fat reduction + IGF-1 elevation) is uniquely relevant for post-weight-loss patients who often have both excess visceral fat and loose abdominal skin. Price per month through a compounding pharmacy is substantially higher than CJC+ipa.

Devices: RF microneedling + red light therapy

Peptides are the biology. Devices are the delivery mechanism and the structural stimulus. For post-weight-loss laxity, there are two device categories worth running alongside peptides: RF (radiofrequency) microneedling for serious structural remodeling, and red light therapy as a daily home adjunct.

RF microneedling

RF microneedling delivers radiofrequency energy to the deep dermis via insulated needles, producing dual thermal and mechanical injury that triggers neocollagenesis. At 1-month follow-up in a Wang 2025 histological study, treatment produced increased dermal thickness, elastin, and collagen fibre thickness and density (Wang et al., 2025). For post-facelift patients with recurrent jowl and neck laxity, a Demesh 2021 prospective study using InMode AccuTite + Morpheus8 showed 33% of patients rated "markedly improved" by blinded investigators at 3 months, rising to 55% at 6 months, with patient-rated improvement hitting 67% at 3 months (Demesh et al., 2021).

Standard body protocol is 3 to 4 sessions spaced 4 to 6 weeks apart. Energy settings and needle depth for abdomen, arms, and inner thighs are higher than facial (typically 3 to 4 mm insertion depth). Morpheus8, Vivace, and Secret RF are the most commonly available insulated platforms. Cost per session in Australia and the US runs USD 800 to 1,800 for body areas; a full 4-session course is a meaningful financial commitment.

The strongest argument for RF microneedling in this context is that it is synergistic with every other layer of the protocol. The microchannels open a window for topical peptide penetration; the thermal injury triggers fibroblast activation that GH peptides then amplify; the healing phase is exactly what BPC-157 is theoretically good at.

Red light therapy

Red light therapy (photobiomodulation) is the cheapest evidence-based home device you can run. A Wunsch 2014 RCT of 136 volunteers doing 30 sessions over 15 weeks at approximately 9 J/cm2 in the 611 to 650 nm range showed improved skin complexion, reduced roughness on profilometry, and measurably increased intradermal collagen density on ultrasound (Wunsch & Matuschka, 2014). A Mota 2023 split-face RCT in 137 women using 660 nm at 3.8 J/cm2 for 10 sessions over 4 weeks produced a 31.6% reduction in periocular wrinkle volume (Mota et al., 2023).

Mechanism: red and near-infrared photons enhance mitochondrial cytochrome c oxidase activity in fibroblasts, increase ATP synthesis, upregulate Col1a1 and Col3a1 gene expression, and reduce IL-6 and TNF-alpha signaling that would otherwise drive collagen degradation.

Practical spec: a consumer device that delivers 660 nm and 830 to 850 nm simultaneously, 10 to 15 minutes per area, daily. Joovv, Mito Red, and PlatinumLED are the most established consumer brands with published irradiance data. Cheaper Amazon panels often overstate their irradiance; look for third-party testing or published spec sheets before buying.

Supplements and training that actually matter

You can run every peptide on this list and it will do nothing if your underlying nutrition and training are wrong. The mechanical volume of muscle under your skin changes perceived laxity more than any peptide does.

Collagen peptides and cofactors

A 2026 RCT comparing 2.5 g/day vs 10 g/day bioactive collagen peptides over 12 weeks found the 10 g/day group significantly reduced wrinkle number (p < 0.0002) and length (p < 0.0424), with elasticity and hydration improvements at both doses (Paula-Vieira et al., 2026). A 2025 RCT at 5 g/day for 12 weeks showed dermal density improvement that persisted through a 4-week washout, suggesting structural change not just transient hydration (Wang et al., 2025). A 2018 90-day RCT with hydrolyzed fish collagen showed +40% skin elasticity vs placebo with histological biopsy confirmation (Czajka et al., 2018).

Practical dose: 10 g/day hydrolyzed collagen peptide (marine or bovine, both work), minimum 12 weeks for structural change.

Vitamin C is not optional. Proline and lysine residues on procollagen chains require vitamin C-dependent hydroxylation to form the stable triple-helix structure of mature collagen. Deficiency disrupts triple-helix formation entirely. Take 500 to 1,000 mg/day with your collagen.

Glycine is the most abundant amino acid in collagen (roughly 33% of residues). Hydrolyzed collagen delivers it pre-formed. If you are not supplementing collagen, add 3 to 5 g glycine daily (pre-bed; also helps sleep quality).

Dietary protein floor

Collagen synthesis is substrate-limited. If your total protein intake is inadequate, your fibroblasts cannot make collagen regardless of how much signaling they are receiving. The floor for post-weight-loss athletes is 1.6 to 2.2 g/kg/day of total protein, which covers both muscle hypertrophy and connective tissue repair. Athletes routinely under-eat protein during cut phases and body recomposition; this is the single most common reason peptide protocols fail.

Track albumin and prealbumin to verify you are actually hitting this target. An albumin below 35 g/L means your body cannot provide adequate amino acid substrate for collagen synthesis, regardless of what peptides you run.

Heavy compound training

Here is the blunt mechanical truth about loose belly skin: the most effective non-surgical intervention is to fill the space underneath it with muscle. You cannot shrink the skin envelope much. You can change what is inside it.

Squat, deadlift, bench, row, overhead press, at progressive loads, 3 to 5 sessions per week. For abdominal hypertrophy specifically: weighted cable crunches, hanging leg raises, decline bench crunches, ab wheel rollouts. High-rep, low-load "toning" work does not produce the tissue volume that displaces loose skin. You need actual hypertrophy of the rectus abdominis.

For arms (tricep laxity is the second-most common complaint after abdomen): close-grip bench, skull crushers, overhead tricep extensions. For inner thighs: adduction work, sumo deadlifts, close-stance squats.

Gaining 3 to 5 kg of lean mass in the trunk and arms over 6 months changes how skin drapes more than any topical does. This is not glamorous, but it works.

Cardio: minimal role

Cardio does not increase skin collagen or muscle volume. Its only role in loose skin management is preventing fat regain. Excessive steady-state cardio during a caloric deficit competes with hypertrophy signaling (AMPK vs mTOR) and can make the problem worse. Keep cardio functional and moderate; put your effort into the weight room.

Bloodwork monitoring on the protocol

If you are running GH secretagogues, you are not in cosmetic territory anymore. You are running a metabolically active intervention that needs monitoring. Fly blind on this and you trade loose skin for insulin resistance, hypothyroidism, or supraphysiological IGF-1 you did not sign up for. See our peptides bloodwork guide for the full monitoring framework; here is the abbreviated version for loose-skin protocols.

Baseline panel before starting (always):

• IGF-1
• Fasting glucose
• HbA1c
• Albumin and prealbumin
• hs-CRP
• TSH and free T4

IGF-1 targeting

The goal is upper-normal-for-age, not supraphysiological. The VARIETE reference data in 911 healthy adults showed assay variability is enormous between labs, especially at the upper limit (Chanson et al., 2016). Use the same lab for serial comparisons. For adults aged 30 to 55, a target of 25 to 35 nmol/L (roughly 190 to 270 ng/mL on IMMULITE) sits in the upper quartile of the age-matched reference range. Above 40 nmol/L (about 350 ng/mL), reduce dose. Above 50 nmol/L, stop.

Blood draw timing is non-negotiable: 12 to 24 hours after the last injection, morning fasted. The GH Research Society 2007 consensus standardised this window (Ho et al., 2007). A sample drawn 2 hours post-injection will be falsely high.

Recheck IGF-1 4 to 6 weeks after any dose change.

Glucose and HbA1c

Baseline + 8 weeks + every 3 months. Flags: fasting glucose above 5.6 mmol/L (100 mg/dL), HbA1c crossing 5.7%, or a rise of more than 0.3% from your baseline. Any of these on a GH secretagogue means pause and reassess. Do not rationalise your way past them. Insulin resistance sneaks up, and post-weight-loss patients are the exact population it will catch first.

Albumin, prealbumin, and hs-CRP

These three markers together tell you whether the substrate and signaling environment actually support collagen remodeling. Albumin below 35 g/L means inadequate protein substrate. Prealbumin below 200 mg/L means acute protein inadequacy (more sensitive than albumin, 2 to 3 day half-life). hs-CRP above 3 mg/L means you are in a pro-inflammatory state that actively antagonises the TGF-beta signaling needed for organised collagen deposition (Zhang et al., 2010).

Interpret albumin and CRP together. Low albumin + high CRP = inflammatory suppression of albumin, not true protein deficiency. Low albumin + low CRP = genuine protein inadequacy that will sabotage the entire protocol. Fix inflammation first if it is present. GLP-1 therapy, weight loss itself, and training all tend to lower CRP over time, which is one of the quieter benefits of running the full protocol over 6 months.

Target on protocol: albumin above 40 g/L, prealbumin above 200 mg/L, hs-CRP below 1.0 mg/L.

When peptides aren't enough: the surgery conversation

No amount of peptide stacking rebuilds destroyed elastin architecture. If your pinch test shows no rebound, your Pittsburgh score is 2 to 3, or you have a true pannus (skin hanging over the waistband), the honest answer is surgical referral.

The clinical milestone is 12 to 18 months post-weight-loss with stable body weight. Dutch healthcare guidelines codify this timeline; a Boswell 2010 review confirmed outcomes are best when body contouring occurs 12 to 18 months post-bariatric surgery (Boswell, 2010). Surgery too early means operating on a body that is still losing; surgery too late means years of functional discomfort from redundant skin.

The most common procedures for this patient population:

• Panniculectomy/abdominoplasty: removal of abdominal skin apron. Often covered by insurance in Australia and the US when there is documented rash/infection from the pannus.
• Brachioplasty: arm lift, addresses bat-wing deformity.
• Thighplasty: medial thigh lift.
• Mastopexy: breast lift, common after major weight loss in both men (gynecomastia correction) and women.

Running peptides up to and through surgery may improve wound healing outcomes, though there is no head-to-head evidence on this. Stop GH secretagogues at least 2 weeks pre-op to avoid any interaction with wound healing signals and to give the surgeon clean baseline IGF-1. BPC-157 and TB-500 are sometimes continued through recovery based on their wound-healing preclinical data, though this is off-label and at your own risk.

Realistic expectations

Here is what 6 months of this protocol looks like in practice for someone with moderate laxity:

• Month 1: Initial "copper uglies" from GHK-Cu, first IGF-1 rise on CJC/ipa, you notice better recovery from training. No visible skin change yet.
• Month 2: Skin texture improves, fine wrinkling reduces, the first RF microneedling session. IGF-1 bloodwork should show clear upper-normal.
• Month 3: First visible improvement in skin firmness. Photographs at this point will look noticeably different from baseline. Second RF session.
• Month 4 to 5: Continued improvement. Muscle gain from training meaningfully changes perceived laxity. Third RF session.
• Month 6: Final assessment. Subjective improvement of 10 to 30% in firmness and texture is realistic. Bloodwork re-check across the full panel.

That is the realistic ceiling for moderate laxity. Severe laxity will see directional improvement but still end at a surgical consultation. Mild laxity will likely look "normal" again. None of this is Photoshopped transformations from Instagram.

Key takeaways

• Loose skin after weight loss is two structural failures: collagen thinning and elastin architecture destruction. Peptides help the first; they cannot rebuild the second.
• Match the protocol to severity: mild laxity gets topicals + training; moderate gets the full stack; severe is a surgical problem with peptides as support.
• Topical GHK-Cu with microneedling is the most evidence-backed layer. Cosmeceutical-grade formulations at 2% are safer than DIY research powders.
• CJC-1295 no-DAC + ipamorelin pre-bed preserves insulin sensitivity that MK-677 destroys. Target upper-normal IGF-1, not supraphysiological.
• BPC-157 and TB-500 have preclinical wound-healing data, not cosmetic loose skin data. Use them as healing adjuncts with eyes open on the evidence gap and cancer-risk signal.
• Collagen peptides (10 g/day) + vitamin C + 1.6 to 2.2 g/kg/day protein is the non-negotiable substrate layer. Fibroblasts cannot build from nothing.
• Heavy compound training and abdominal hypertrophy change skin drape more than any topical does.
• Monitor IGF-1, fasting glucose, HbA1c, albumin, prealbumin, hs-CRP, TSH, and free T4. GH secretagogues are metabolically active; do not fly blind.
• Give the protocol 12 to 18 months before evaluating surgery. The body partially recovers if given time and adequate protein.

---

References

1. Rocha, R. I., Cintra, W., Jr., Modolin, M. L. A., Takahashi, G. G., Caldini, E. T. E. G., & Gemperli, R. (2021). Skin changes due to massive weight loss: Histological changes and the causes of the limited results of contouring surgeries. Obesity Surgery, 31(3), 1366-1373. PubMed

2. Orpheu, S. C., Coltro, P. S., Scopel, G. P., et al. (2010). Collagen and elastic content of abdominal skin after surgical weight loss. Obesity Surgery, 20(4), 480-486. PubMed

3. Sami, K., Elshahat, A., Moussa, M., Abbas, A., & Mahmoud, A. (2015). Image analyzer study of the skin in patients with morbid obesity and massive weight loss. Eplasty, 15, e3. PubMed

4. Hany, M., Zidan, A., Ghozlan, N. A., et al. (2024). Comparison of histological skin changes after massive weight loss in post-bariatric and non-bariatric patients. Obesity Surgery, 34(3), 905-914. PubMed

5. Varani, J., Dame, M. K., Rittie, L., et al. (2006). Decreased collagen production in chronologically aged skin. American Journal of Pathology, 168(6), 1861-1868. PubMed

6. Song, A. Y., Jean, R. D., Hurwitz, D. J., et al. (2005). A classification of contour deformities after bariatric weight loss: The Pittsburgh Rating Scale. Plastic and Reconstructive Surgery, 116(5), 1424-1431. PubMed

7. Boswell, C. B. (2010). Body contouring following massive weight loss. Missouri Medicine, 107(3), 189-194. PubMed

8. Maquart, F. X., Pickart, L., Laurent, M., et al. (1988). Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters, 238(2), 343-346. PubMed

9. Maquart, F. X., Bellon, G., Chaqour, B., et al. (1993). In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. Journal of Clinical Investigation, 92(5), 2368-2376. PubMed

10. Pickart, L. (2008). The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science: Polymer Edition, 19(8), 969-988. PubMed

11. Byun, S. Y., Chae, J. B., Na, J. I., & Park, K. C. (2016). Significant improvement in crow's feet after treatment with Jet-M and a mixed solution of copper-GHK and related actives. Journal of Cosmetic and Laser Therapy, 18(5), 293-295. PubMed

12. Hur, G. H., Han, S. C., Ryu, A. R., et al. (2020). Effect of oligoarginine conjugation on the antiwrinkle activity and transdermal delivery of GHK peptide. Journal of Peptide Science, 26(2), e3234. PubMed

13. Quinlan, D. J., Ghanem, A. M., & Hassan, H. (2022). Topical growth factors and home-based microneedling for facial skin rejuvenation. Journal of Cosmetic Dermatology, 21(8), 3469-3478. PubMed

14. Huang, T., Zhang, K., Sun, L., et al. (2015). Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Design, Development and Therapy, 9, 2485-2499. PubMed

15. Mikus, D., Sikiric, P., Seiwerth, S., et al. (2001). Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice. Burns, 27(8), 817-827. PubMed

16. Seveljević-Jaran, D., Cuzić, S., Dominis-Kramarić, M., et al. (2006). Accelerated healing of excisional skin wounds by PL 14736 in alloxan-hyperglycemic rats. Skin Pharmacology and Physiology, 19(5), 266-274. PubMed

17. Kleinman, H. K., & Sosne, G. (2016). Thymosin beta 4 promotes dermal healing. Vitamins and Hormones, 102, 251-275. PubMed

18. Cha, H. J., Jeong, M. J., & Kleinman, H. K. (2003). Role of thymosin beta4 in tumor metastasis and angiogenesis. Journal of the National Cancer Institute, 95(22), 1674-1680. PubMed

19. Lee, E., & Burgess, K. (2025). Safety of intravenous infusion of BPC157 in humans: A pilot study. Alternative Therapies in Health and Medicine, 31(5), 20-24. PubMed

20. Teichman, S. L., Neale, A., Lawrence, B., et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism, 91(3), 799-805. PubMed

21. Raun, K., Hansen, B. S., Johansen, N. L., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561. PubMed

22. Doessing, S., Heinemeier, K. M., Holm, L., et al. (2010). Growth hormone stimulates the collagen synthesis in human tendon and skeletal muscle without affecting myofibrillar protein synthesis. Journal of Physiology, 588(Pt 2), 341-351. PubMed

23. Blackstock, C. D., Higashi, Y., Sukhanov, S., et al. (2014). Insulin-like growth factor-1 increases synthesis of collagen type I via induction of the mRNA-binding protein LARP6 expression and binding to the 5' stem-loop of COL1a1 and COL1a2 mRNA. Journal of Biological Chemistry, 289(10), 7203-7211. PubMed

24. Nass, R., Pezzoli, S. S., Oliveri, M. C., et al. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: A randomized trial. Annals of Internal Medicine, 149(9), 601-611. PubMed

25. Chapman, I. M., Bach, M. A., Van Cauter, E., et al. (1996). Stimulation of the GH-IGF-I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. Journal of Clinical Endocrinology and Metabolism, 81(12), 4249-4257. PubMed

26. Falutz, J., Allas, S., Blot, K., et al. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: A pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials. Journal of Clinical Endocrinology and Metabolism, 95(9), 4291-4304. PubMed

27. Porretti, S., Giavoli, C., Ronchi, C., et al. (2002). Recombinant human GH replacement therapy and thyroid function in a large group of adult GH-deficient patients. European Journal of Endocrinology, 146(4), 483-490. PubMed

28. Wang, M., Li, Y., Lai, X., Shi, C., & Yan, Y. (2025). The clinical effects and skin histological changes induced by a novel insulated radiofrequency microneedle. Lasers in Medical Science, 40(1), 98. PubMed

29. Demesh, D., Cristel, R. T., Gandhi, N. D., Kola, E., & Dayan, S. H. (2021). The use of radiofrequency-assisted lipolysis with radiofrequency microneedling in premature jowl and neck laxity following facialplasty. Journal of Cosmetic Dermatology, 20(1), 93-98. PubMed

30. Wunsch, A., & Matuschka, K. (2014). A controlled trial to determine the efficacy of red and near-infrared light treatment for skin rejuvenation. Photomedicine and Laser Surgery, 32(2), 93-100. PubMed

31. Mota, L. R., Duarte, I. D. S., Galache, T. R., et al. (2023). Photobiomodulation reduces periocular wrinkle volume by 30%: A randomized controlled trial. Photobiomodulation, Photomedicine, and Laser Surgery, 41(2), 48-56. PubMed

32. Paula-Vieira, R. H. R., Dias, S. R., Silva-Reis, A., et al. (2026). Immune-modulatory effects of bioactive collagen peptides improve skin health in middle-aged women. Dermatology and Therapy, 16(2), 1385-1397. PubMed

33. Wang, Y., Zhu, W., Luo, W., Ma, Y., & Zhou, Y. (2025). The sustained effects of bioactive collagen peptides on skin health: A randomized, double-blind, placebo-controlled clinical study. Journal of Cosmetic Dermatology, 24(12), e70565. PubMed

34. Czajka, A., Kania, E. M., Genovese, L., et al. (2018). Daily oral supplementation with collagen peptides combined with vitamins and other bioactive compounds improves skin elasticity (note: multi-ingredient formulation). Nutrition Research, 57, 97-108. PubMed

35. Chanson, P., Arnoux, A., Mavromati, M., et al. (2016). Reference values for IGF-I serum concentrations: Comparison of six immunoassays. Journal of Clinical Endocrinology and Metabolism, 101(9), 3450-3458. PubMed

36. Ho, K. K. (2007). Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: A statement of the GH Research Society. European Journal of Endocrinology, 157(6), 695-700. PubMed

37. Zhang, R., Zhang, Y. Y., Huang, X. R., et al. (2010). C-reactive protein promotes cardiac fibrosis and inflammation in angiotensin II-induced hypertensive cardiac disease. Hypertension, 55(4), 953-960. PubMed